Table 1. Clinical data on both study groups.
Group 1 (n=506) ≤21 days | Group 2 (n=501) >21 days | P-value | |
---|---|---|---|
Storage time (mean±SD) | 16.8±3 days | 24.4±2,7 days | <0.001 |
Post-mortem time (mean±SD) | 27±15 days | 28±17 days | 0.98 |
Donor age (mean±SD) | 64±17 years | 63±18 years | 0.47 |
Patient age (mean±SD) | 59±19 years | 58±19 years | 0.50 |
Follow-up (median, lower, and upper quartile) | 540 (264, 848) days | 509 (264, 809) days | 0.34 |
Percentage of normal risk patients | 31% (n=159) | 32% (n=158) | 0.97 |
Percentage of matched grafts (≤2 mismatches)a | 34% | 33% | 0.83 |
Immune reaction after 2 yearsb (percentage, 95% confidence interval) | 26.5 (21.6–31.2)% | 20.1 (15.5–24.5)% | NA |
Immune reaction after 3 yearsb (percentage±95 confidence interval) | 32.6 (25.9–38.6)% | 25.9 (18.9–32.3)% | NA |
There was a statistical significant difference regarding the occurrence of endothelial immune reactions between the two groups. All other parameters were not statistically significantly different.
Matching did not distinguish between HLA class I and HLA class II.
Estimates from Kaplan–Meier survival analysis.